{"id":"escherichia-coli-esbl","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5315102","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ESBL-producing E. coli are bacteria resistant to many beta-lactam antibiotics. The mechanism likely involves either direct antimicrobial activity against these resistant strains or immunological approaches to enhance clearance of ESBL-producing pathogens. Given the phase 2 status and unconventional designation, this may represent a novel therapeutic modality such as a vaccine, bacteriophage therapy, or immunobiological agent rather than a traditional small-molecule antibiotic.","oneSentence":"This appears to be a therapeutic intervention targeting extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:51:49.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli"}]},"trialDetails":[{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":"E Coli Infection, ESBL Producing E.Coli","enrollment":84},{"nctId":"NCT07106944","phase":"","title":"Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-08-11","conditions":"Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae","enrollment":100},{"nctId":"NCT04764500","phase":"","title":"Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-13","conditions":"Extended Spectrum Beta Lactamases (ESBL) E. Coli","enrollment":39},{"nctId":"NCT04323553","phase":"","title":"Comparison of Pulsed-field Gel Electrophoresis and Whole Genome Sequencing to Determine Transmission Rate of ESBL-producing E.Coli","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-03-06","conditions":"Analysis Transmission Rate","enrollment":43},{"nctId":"NCT06044272","phase":"","title":"Antimicrobial Resistance in Hospitals From Meta, Colombia","status":"COMPLETED","sponsor":"Hospital Departamental de Villavicencio","startDate":"2023-09-01","conditions":"Increased Drug Resistance","enrollment":10000},{"nctId":"NCT03891433","phase":"PHASE4","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","status":"SUSPENDED","sponsor":"Universidad del Norte","startDate":"2019-04-01","conditions":"Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria","enrollment":198},{"nctId":"NCT06305455","phase":"","title":"Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship","status":"NOT_YET_RECRUITING","sponsor":"José Raimundo Araujo de Azevedo","startDate":"2024-04","conditions":"Antimicrobial Resistance","enrollment":200},{"nctId":"NCT03477084","phase":"","title":"Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-03-01","conditions":"Resistance Bacterial, Enterobacteriaceae Infections","enrollment":160},{"nctId":"NCT04574596","phase":"","title":"Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-11-12","conditions":"E Coli Infection","enrollment":300},{"nctId":"NCT00573235","phase":"","title":"Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-10","conditions":"Enterobacteriaceae Infections","enrollment":300},{"nctId":"NCT01820793","phase":"NA","title":"Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-05","conditions":"Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli","enrollment":9},{"nctId":"NCT02474706","phase":"PHASE4","title":"Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli","status":"TERMINATED","sponsor":"Central Hospital, Nancy, France","startDate":"2016-03","conditions":"Urinary Tract Infections","enrollment":6},{"nctId":"NCT01531023","phase":"","title":"Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2013-04","conditions":"Urinary Tract Infections","enrollment":168},{"nctId":"NCT02456818","phase":"","title":"Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards","status":"UNKNOWN","sponsor":"University of Cologne","startDate":"2015-01","conditions":"Oncology [See Also, Affected System], Hematological Disease, Infection Due to ESBL Escherichia Coli","enrollment":2264},{"nctId":"NCT00363220","phase":"","title":"Community - Associated Extended-spectrum Beta-lactamases (ESBL)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-08","conditions":"Infection, E Coli Infections, Klebsiella Infections","enrollment":100},{"nctId":"NCT01961206","phase":"","title":"Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis","status":"COMPLETED","sponsor":"Jian-cang Zhou M.D.","startDate":"2013-10","conditions":"Community Acquired Infection","enrollment":960},{"nctId":"NCT01324726","phase":"","title":"Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2012-07","conditions":"Escherichia Coli Infections, Klebsiella Pneumonia","enrollment":100},{"nctId":"NCT00167999","phase":"","title":"Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-02","conditions":"Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections","enrollment":200},{"nctId":"NCT00167986","phase":"","title":"Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-01","conditions":"Escherichia Coli Infections, Klebsiella Infections","enrollment":480},{"nctId":"NCT00300560","phase":"PHASE3","title":"Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2006-02","conditions":"Infections","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":356,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Escherichia coli ESBL","genericName":"Escherichia coli ESBL","companyName":"José Raimundo Araujo de Azevedo","companyId":"jos-raimundo-araujo-de-azevedo","modality":"Biologic","firstApprovalDate":"","aiSummary":"This appears to be a therapeutic intervention targeting extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli infections. Used for Infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}